Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis

Ga Young Song, Sung Hoon Jung, Je Jung Lee, Jin Seok Kim, Chang Ki Min, Kihyun Kim, Yunsuk Choi, Hyeon Seok Eom, Young Don Joo, Sung Hyun Kim, Jae Yong Kwak, Hye Jin Kang, Jae Hoon Lee, Ho Sup Lee, Yeung Chul Mun, Joon Ho Moon, Sang Kyun Sohn, Seong Kyu Park, Yong Park, Ho Jin ShinSung Soo Yoon

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the efficacy and toxicity of busulfan and melphalan (BUMEL) and those of high-dose melphalan (HDMEL) as conditioning regimens for autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM) through a propensity score-matched analysis. No significant difference in the complete response and overall response rate after ASCT was observed between BUMEL and HDMEL. After a median follow-up of 37.3 months in the BUMEL group and 50.8 months in the HDMEL group, the median progression-free survival was calculated to be 32.9 months and 25.2 months (p = 0.995). With respect to non-hematologic toxicities, infections were more frequently reported in the BUMEL group (p < 0.001). Three patients who received BUMEL developed veno-occlusive disease (VOD), and all of them recovered without administration of defibrotide. In conclusion, BUMEL is an effective alternative conditioning regimen in terms of efficacy, but attention should be paid to toxicities.

Original languageEnglish
Pages (from-to)2714-2721
Number of pages8
JournalLeukemia and Lymphoma
Volume61
Issue number11
DOIs
Publication statusPublished - 2020 Nov

Keywords

  • Multiple myeloma
  • autologous stem cell transplantation
  • conditioning regimen

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis'. Together they form a unique fingerprint.

Cite this